Bricanyl (terbutaline) is a core component of therapeutic support used in clinical contexts marked by heightened patient distress due to respiratory symptoms. It is applied across domains where short-term symptomatic assistance is appropriate, helps patients cope more steadily with difficult episodes, and is commonly used.

Terbutaline is used to prevent and treat conditions that cause wheezing, shortness of breath, and chest tightness.

Addressing Acute Breathing Difficulties and Wheezing

This medication is applied in clinical settings that involve acute or unstable symptom patterns, serving as a vital rescue therapy. It is used when symptoms create noticeable interference with daily stability, specifically targeting the symptoms of wheezing, chest tightness, and acute shortness of breath (dyspnea). The key therapeutic benefit is that it provides supportive relief that helps ease the acute symptoms, which may assist patients with coping more steadily with difficult episodes.

Supporting Conditions Characterized by Episodic Bronchospasm

Bricanyl is commonly used across conditions characterized by episodic or fluctuating symptom patterns, most notably in asthma and Chronic Obstructive Pulmonary Disease (COPD). It is applied during phases where the patient experiences heightened discomfort, and is applied for short-term symptomatic assistance during acute episodes. This use provides support that helps the patient during difficult episodes by easing distress, and may assist with maintaining functional stability and comfort during periods of heightened symptoms.

Quick Fact: Provides supportive relief for symptoms related to heightened physiological activity and respiratory distress.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules for Bricanyl (Terbutaline)

The population eligibility for Bricanyl is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditions that require conditional use. Eligibility is primarily restricted based on hypersensitivity, specific historical use, and the presence of underlying health conditions.

Contraindications (Must Not Use)

Conditional Use (Requires Caution)

Age and Reproductive Status

Bricanyl is generally approved for adults and adolescents (12 years and older). Use is often not recommended for children under 12 for oral forms. During pregnancy, use is restricted and generally allowed only if the benefit outweighs the risk to the fetus, except where use is specifically contraindicated (tocolysis).

Interactions with other medicines and products

The official regulatory documents define several critical pharmacodynamic interactions for terbutaline sulfate.

Prohibited and Restricted Combinations

• Non-selective beta-blockers are generally not recommended for co-administration. These agents may block the pulmonary effect of beta2-agonists and can potentially induce severe bronchospasm.
• Concomitant use with other sympathomimetic agents is not recommended because the combined stimulatory effect on the cardiovascular system is potentially deleterious.
• The use of Halogenated Anaesthetics must be avoided during terbutaline treatment due to an increased risk of cardiac arrhythmias.

Interactions Requiring Caution

• Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) requires extreme caution. These drug classes may potentiate the vascular system’s response to terbutaline. Caution is also required if terbutaline is administered within two weeks of discontinuing MAOIs or TCAs.
• Diuretics (non-potassium sparing), Corticosteroids, and Xanthine Derivatives may potentiate the hypokalemic effect associated with beta2-agonist therapy.

Regulatory Summary

The interaction profile is structured around mandatory constraints and necessary cautionary measures dictated by pharmacodynamic effects. Regulatory documentation classifies combinations based on pharmacodynamic antagonism (e.g., beta-blockers) or enhancement of systemic effects (e.g., vascular potentiation or hypokalemia risk). No specific interaction patterns with food, alcohol, or herbal products are consistently documented by regulators that require mandatory separation or prohibition.

Бриканил (Terbutaline) is a selective beta2-adrenergic receptor agonist that acts primarily by modulating signal transduction pathways associated with the sympathetic nervous system.

Targeting beta2-Adrenergic Receptors

The drug acts within domains involving receptor-mediated signaling by selectively binding to and activating beta2-adrenergic receptors on the surface of smooth muscle cells, affecting pathways in tissues where this receptor subtype predominates. This initiates a signaling cascade that modulates key pathways associated with cellular activity.

Regulation of Cyclic AMP Signaling

Activation of the beta2-receptors causes the downstream activation of the enzyme adenylyl cyclase. This modifies early molecular steps by increasing the intracellular concentration of cyclic adenosine monophosphate (cAMP). Increased cAMP supports the modulation of cellular processes driven by distinct signaling patterns within the cell.

Regulation of Smooth Muscle Tone

The elevated cAMP levels modulate regulatory proteins, influencing contractile filament activity. Specifically, cAMP activates protein kinase A (PKA), which ultimately leads to a decrease in intracellular calcium ion concentration. This sequence results in the dephosphorylation of myosin light chain, thereby reducing the contractile state of bronchial smooth muscle cells.

How Terbutaline (Bricanyl) is Officially Used

Terbutaline is administered via three primary official routes: oral (tablets), subcutaneous (SC) injection, and inhalation (nebulization solution), with specific dosing and scheduling constraints for each route.

Official Administration and Dosing Regimens

Administration Rules and Context

Oral tablets are typically taken three times daily, with doses spaced approximately six hours apart during waking hours. If adverse effects are observed, the adult oral dose may be reduced to 2.5 mg three times daily. The subcutaneous injection is administered under the skin, often into the lateral deltoid area, with a constraint allowing a second 0.25 mg dose only 15 to 30 minutes after the first, if required.

For inhalation, the solution is preservative-free and supplied in single-dose units. These nebulization units must be used within 24 hours after the protective foil pouch is opened.

Population-Specific Use

Adjustments are noted for specific groups. For oral tablets, pediatric patients aged 12 to 15 years have a lower maximum daily dose of 7.5 mg total. Importantly, a diminished response to the usual dose of terbutaline is identified as a signal that the patient’s overall regimen requires a mandatory reevaluation by a healthcare provider, rather than a simple dose increase.

Research Evidence / Overview of Studies for Бриканил (Terbutaline)

Evidence for Use in Acute Relief of Bronchospasm

Terbutaline, the active ingredient in Бриканил, was studied for its use in exploring how symptoms change during periods of acute breathing difficulties.

The core evidence was studied through Randomized Controlled Trials (RCTs) and Systematic Reviews that research examined how symptoms change over short time intervals. These studies primarily focused on adults and adolescents who were experiencing periods of heightened symptom activity. The research focused on changes in objective pulmonary function indexes, such as how much air a person can exhale in one second, as well as patient-reported outcomes describing perceived discomfort.

Comparative studies exploring short-term symptom changes research examined responses when evaluated against various short-acting rescue agents. Follow-up durations were limited to the immediate period of acute distress, consistent with its intended use. Limited insight exists into how this medicine, when used for acute relief, was studied for long-term outcomes related to the overall course of the underlying respiratory condition.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD) Support

Terbutaline was evaluated in research contexts involving individuals with Chronic Obstructive Pulmonary Disease (COPD), a condition characterized by fluctuating manifestations. Studies explored its use both for daily support and during periods where symptoms become more noticeable, such as an acute flare-up (exacerbation). This research often involved RCTs that measured objective changes in lung function and arterial blood gas indexes.

The regulatory assessment of evidence for this use is classified as Moderate. This reflects the clear physiological changes observed in some studies regarding bronchodilation, but also acknowledges that data for certain groups remain insufficient. Comparative evidence is lacking when trying to position terbutaline against the long-acting maintenance therapies that are currently the focus of major international treatment guidelines for COPD.

Key Studies & References Terbutaline Drug Information (MedlinePlus)

Common questions about Бриканил (FAQ)

Q: Can I take this medication while pregnant or breastfeeding?

According to the official product information, this medication is generally not recommended for use during pregnancy or breastfeeding. The prescribing information advises that breastfeeding is typically not recommended during treatment because the medicine may pass into breast milk. Consultation with a healthcare professional is necessary for specific guidance in this situation.

Q: Is it safe to take this medication long-term?

Regulatory documents indicate this medication is used to treat chronic conditions like hyperlipidemia and to help with cardiovascular risk reduction, which often require treatment over an extended period. Clinical studies support its use for these conditions. However, the duration of treatment is determined by the prescriber and may involve periodic monitoring of certain functions, such as liver and muscle function, as outlined in the official prescribing information.

Q: Can children 2 years old use it?

Official regulatory documents generally indicate this medication is not recommended for children younger than 10 years old. It is typically indicated for use in pediatric patients aged 10 years and older to treat specific conditions, such as Heterozygous Familial Hypercholesterolemia (HeFH). Information regarding dosing and use in children under 10 years of age is generally not provided in the official prescribing documents.

How to Store and Dispose of Bricanyl (Terbutaline)

Official regulatory documents define specific temperature and packaging requirements for Bricanyl based on its formulation. All forms of the medication must be kept out of the sight and reach of children.

Storage Requirements by Formulation

Disposal

There are no special requirements for the disposal of Bricanyl. Any unused or expired medicinal product or waste material must be disposed of in accordance with local requirements.